Potential anxiolytic‐ and antidepressant‐like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents
Daniela Braida, Valeria Capurro, Alessia Zani, Tiziana Rubino, Daniela Viganò, Daniela Parolaro, Mariaelvina Sala
British Journal of Pharmacology May 5, 2009 DOI: 10.1111/j.1476-5381.2009.00230.x via OpenAlex
Summary
AI-generated from the abstractSalvinorin A, the active ingredient in Salvia divinorum, produced both anxiety-reducing and antidepressant-like effects in rats and mice. These effects were prevented by blocking either kappa-opioid or CB1 cannabinoid receptors. Salvinorin A reduced fatty acid amide hydrolase activity in the amygdala but showed very weak binding to CB1 receptors. The findings suggest that both kappa-opioid and endocannabinoid systems mediate these mood-altering effects, which may help explain subjective experiences reported by recreational users.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Male Sprague-Dawley rats and male Albino Swiss mice |
| Intervention | Salvinorin A |
| Dose | 0.001-1000 microgxkg(-1) |
| Keywords | Pharmacology Κ-opioid receptor Am251 Anxiolytic Chemistry |
| Citations | 145 |
| Key finding | Salvinorin A exhibits anxiolytic- and antidepressant-like effects mediated by both kappa-opioid and endocannabinoid systems. |
Abstract
BACKGROUND AND PURPOSE: Drugs targeting brain kappa-opioid receptors produce profound alterations in mood. In the present study we investigated the possible anxiolytic- and antidepressant-like effects of the kappa-opioid receptor agonist salvinorin A, the main active ingredient of Salvia divinorum, in rats and mice. EXPERIMENTAL APPROACH: Experiments were performed on male Sprague-Dawley rats or male Albino Swiss mice. The anxiolytic-like effects were tested by using the elevated plus maze, in rats. The antidepressant-like effect was estimated through the forced swim (rats) and the tail suspension (mice) test. kappa-Opioid receptor involvement was investigated pretreating animals with the kappa-opioid receptor antagonist, nor-binaltorphimine (1 or 10 mgxkg(-1)), while direct or indirect activity at CB(1) cannabinoid receptors was evaluated with the CB(1) cannabinoid receptor antagonist, N-(piperidin-1-yl) -5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, 0.5 or 3 mgxkg(-1)), binding to striatal membranes of naïve rats and assay of fatty acid amide hydrolase in prefrontal cortex, hippocampus and amygdala. KEY RESULTS: Salvinorin A, given s.c. (0.001-1000 microgxkg(-1)), exhibited both anxiolytic- and antidepressant-like effects that were prevented by nor-binaltorphimine or AM251 (0.5 or 3 mgxkg(-1)). Salvinorin A reduced fatty acid amide hydrolase activity in amygdala but had very weak affinity for cannabinoid CB(1) receptors. CONCLUSIONS AND IMPLICATIONS: The anxiolytic- and antidepressant-like effects of Salvinorin A are mediated by both kappa-opioid and endocannabinoid systems and may partly explain the subjective symptoms reported by recreational users of S. divinorum.